Xxxxxx Laboratories. (EU) LTD., having a place of business at Xxxxxxxxx Xxxx, Xxxxxxxx, Xxxx Xxxxxxxxx, XX00 0XX, XX (hereinafter referred to as "LICENSOR" or "Xx. Xxxxx'x" which expression shall unless contrary to the meaning and context thereof mean and include its successors, representatives and permitted assigns) of the One Part. ISORAY MEDICAL INC., having its registered office at 000 Xxxxx Xx, Xxxx000, Xxxxxxxx XX 00000, XXX, (hereinafter referred to as "LICENSEE" or "IsoRay" which expression shall unless contrary to the meaning and context thereof mean and include its successors, representatives and permitted assigns) of Other Part; Within this Agreement the LICENSOR and the LICENSEE shall be collectively referred to as the Parties and the term Party shall refer to either of them as the context permits.
Xxxxxx Laboratories. 1,710 65,989.40 Xxxxxxx-Xxxxx Squibb Company .............. 2,620 65,997.80 Schering-Plough Corporation ............... 2,870 66,153.50 Retail--Major Department Store (6.66%) .......
Xxxxxx Laboratories. 750 32,924.90 Publishing-Newspapers (3.31%) ............................. Gannett Co., Inc. ..................................... 520 32,973.20 EQUITY OPPORTUNITY TRUST DIVIDEND INCOME VALUE STRATEGY SERIES 2006B SCHEDULE OF INVESTMENTS--CONTINUED PRIMARY INDUSTRY SOURCE/PERCENTAGE OF AGGREGATE NET ASSET NUMBER OF COST OF SECURITIES VALUE OF THE TRUST AND NAME OF ISSUER SHARES TO TRUST(1)(2)(3) ----------------------------------------------------------- ----------- -------------------
Xxxxxx Laboratories. 760 33,143.20 Xxxxxxx-Xxxxx Squibb Company ............. 1,170 32,900.40 Pfizer Inc. .............................. 910 33,351.50 EQUITY OPPORTUNITY TRUST DIVIDEND INCOME VALUE STRATEGY SERIES 2004B SCHEDULE OF INVESTMENTS--CONTINUED
Xxxxxx Laboratories. Dx. Xxxxx’x Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: wxx.xxxxxxxx.xxx.
Xxxxxx Laboratories. LIMITED, a Company incorporated under the Companies Act, 1956 and having its registered office at 0-0-00, Xxxxxxxx, Xxxxxxxxx, Xxxxxx Xxxxxxx — 500 016 (hereinafter referred to as the “Issuer / Company” which expression shall unless excluded by or repugnant to the context or meaning thereof, be deemed to include its successors and assignees) of the ONE PART; and
Xxxxxx Laboratories. LIMITED, a company incorporated under the Companies Act, 1956 and an existing company under the Companies Axx, 0000, bearing corporate identification number L85195AP1984PLC004507 and having its registered office situated at 8-0-000, Xxxx xx. 0, Xxxxxxx Xxxxx, Xxxxxxxxx 500 034, Telangana, India (hereinafter referred to as the “Purchaser”, which expression shall, unless inconsistent with the meaning or context thereof, be deemed to include its successors and permitted assigns) of the SECOND PART; The Seller and the Purchaser are hereinafter referred to individually as a “Party” and collectively as the “Parties”.
Xxxxxx Laboratories. LIMITED, a company registered under the Companies Xxx, 0000, with its registered office at 0-0-00, Xxxxxxxx, Xxxxxxxxx, Xxxxxx Xxxxxxx (hereinafter referred to as the “Company” which expression shall be deemed to include its successors and permitted assigns); AND
Xxxxxx Laboratories. Notwithstanding the Confidentiality Agreement between the Parties or any provision of this Agreement, XXX acknowledges that CRTX has, with DEY's consent, contacted Xxxxxx Laboratories to discuss the terms of the transaction contemplated by this Agreement pursuant to Xxxxxx'x rights to co-commercialize Zileuton XR. Prior to the public announcement of this Agreement, CRTX represents that it has not identified, and will not identify, XXX or any of its products, to Abbott. CRTX shall not disclose any XXX Proprietary Information to Abbott without DEY's prior written consent.
